Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etanercept: efficacy and safety.

R Jiménez-Puya1, F Gómez-García, V Amorrich-Campos

  • 1Service of Dermatology, University Hospital of Cordoba, Cordoba, Spain. jimpuya@terra.es

Journal of the European Academy of Dermatology and Venereology : JEADV
|February 13, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Evaluation of spino-pelvic mobility; its importance in preventing total hip replacement dislocation].

Acta ortopedica mexicana·2024
Same author

Evolution of appraisal tool usage preferences in PROSPERO records: a study of non-Cochrane systematic reviews.

BMC medical research methodology·2023
Same author

[Dual mobility cup: successes, risks and lessons learned].

Acta ortopedica mexicana·2023
Same author

[History and development of hip arthroplasty: a vision of its successes, failures and teachings. (Part two)].

Acta ortopedica mexicana·2022
Same author

[History and development of hip arthroplasty. An overview of its successes, failures and lessons learned. (Part one)].

Acta ortopedica mexicana·2022
Same author

[Installed Capacity Perception Survey for the Training of Residents Program in Orthopedics and Care Needs in Acute and Chronic Musculoskeletal Pathology in Mexico].

Acta ortopedica mexicana·2020

Etanercept effectively treats moderate to severe plaque psoriasis, showing significant improvements in skin condition and safety. Both 50 mg and 100 mg weekly doses yielded comparable long-term results in patients.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Etanercept is a biologic therapy used for moderate to severe plaque psoriasis.

Purpose of the Study:

  • To evaluate the efficacy and safety of etanercept in treating moderate to severe plaque psoriasis.
  • To compare two dosage regimens of etanercept (50 mg vs. 100 mg weekly).

Main Methods:

  • Observational, longitudinal, retrospective study of 58 patients with moderate to severe plaque psoriasis.
  • Efficacy assessed using Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician's Global Assessment (PGA) at multiple time points.
  • Safety monitored throughout the 48-week treatment period.

Related Experiment Videos

Main Results:

  • Statistically significant improvements in PASI, BSA, and PGA observed by week 24 and sustained at week 48.
  • After 48 weeks, PASI 50, 75, and 90 responses were 100%, 92.3%, and 69.2%, respectively.
  • Both 50 mg and 100 mg weekly doses showed comparable efficacy, with a faster initial response at the higher dose. Etanercept was well-tolerated with no serious adverse events.

Conclusions:

  • Etanercept demonstrates significant efficacy and a favorable safety profile in treating moderate to severe plaque psoriasis.
  • Both evaluated doses of etanercept are effective, with comparable long-term outcomes.
  • Adverse events were consistent with known side effects, and no serious safety concerns were identified.